Merck’s latest deal turns up the spotlight on immune system drugmakers

Inflammation and immunology “has been an attractive and rewarding therapeutic area over the last 12 months,” according to Yee, who, in a note to clients, highlighted a recent string of drug studies that generated positive results. The Prometheus deal, he wrote, underscores the “high value, big markets” within immunology, as well as the need for new medicines.